Lurbinectedin

芦比替定

Report date: 2026/05/28 20:00:21
NME

Base Information

Drug NameLurbinectedin
Drug Alias Name卢比克替定TryptamicidinlurbinectedinalurbinectedinumZepzelca +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA minor groove bindersDNA-binding proteins modulators +[4] 
TargetsDNA minor grooveDNA-binding proteins
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Metastatic breast cancerGastroenteropancreatic neuroendocrine tumor +[26] 
Global Approved IndicationsSmall Cell Lung Carcinoma
Approved Indications in ChinaSmall Cell Lung Carcinoma
Original Approved Country/TerritoryUnited States
Original Approved Date2020/06/15
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPharma Mar Sa
China Registration ClassN/A

Develop Information

Active CompaniesSamsung Medical CenterEczacibasi Pharmaceuticals MarketingChugai Pharmaceutical Co Ltd +[18] 
Inactive CompaniesUniversity Of California San FranciscoPharmaMar AG
Active IndicationsPancreatic neuroendocrine tumors (pNET)Gastroenteropancreatic neuroendocrine tumorSolid tumours +[18] 
Inactive IndicationsMetastatic breast cancerGenital Neoplasms, FemaleCarcinoma, Non-Small-Cell Lung +[8] 

Other Information

ATC CodeL01XX
Related LinksWikipediaDrugBankKEGG